Molecule Details
| InChIKey | PIJVFDBKTWXHHD-HIFRSBDPSA-N |
|---|---|
| Compound Name | Physostigmine |
| Canonical SMILES | CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 3 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 7.19 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB00981 |
|---|---|
| Drug Name | Physostigmine |
| CAS Number | 57-47-6 |
| Groups | approved |
| ATC Codes | S01EB05 V03AB19 |
| Description | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. |
Categories: Acids, Acyclic Alkaloids Antidotes Antiglaucoma Preparations and Miotics Autonomic Agents Carbamates Cholinergic Agents Cholinesterase Inhibitors Enzyme Inhibitors Heterocyclic Compounds, Fused-Ring Indole Alkaloids Indoles Indolizidines Indolizines Miotics Neurotransmitter Agents Ophthalmologicals Parasympathomimetics Peripheral Nervous System Agents Phenylcarbamates Sensory Organs
Cross-references: BindingDB: 50222010 ChEBI: 27953 CHEMBL94 ChemSpider: 5763 Drugs Product Database (DPD): 10016 C06535 D00196 PharmGKB: PA450957 PubChem:5983 PubChem:46506998 RxCUI: 8299 Therapeutic Targets Database: DAP000561 Wikipedia: Physostigmine ZINC: ZINC000091689892